ASX:KZA NASDAQ:KZIA

Kazia Therapeutics Ltd

Market:

ASX

Market Cap:

$68.2 m

Price

0.95 AUD

Change

0.00%

52 weeks high

1.24

52 weeks low

0.37

08.26

Director Interviews

In brief

Kazia Therapeutics (ASX: KZA, NASDAQ: KZIA) pipeline includes two clinical-stage drug development candidates.

In brief Deep dive Research Latest news Insight Interviews

Deep dive We explore the investor case for growth companies

Kazia Therapeutics sees 2020 as crucial inflection point for oncology programs

Kazia Therapeutics Ltd - Kazia Therapeutics sees 2020 as an exciting period and crucial inflection point for its oncology programs

Snapshot

The biotech has delivered all milestones to date, with multiple data read-outs expected over 6-12 months.

Watch

Kazia Therapeutics Ltd - Kazia Therapeutics CEO hails Fast Track Designation for Paxalisib

Director Interviews Kazia Therapeutics CEO hails Fast Track Designation for Paxalisib

on 21/8/20

Kazia Therapeutics Ltd - Kazia Therapeutics working on moving its flagship Paxalisib drug into pivotal trial for registration

Director Interviews Kazia Therapeutics working on moving its flagship Paxalisib drug into pivotal trial for registration

on 4/6/20

Kazia Therapeutics Ltd - Kazia Therapeutics releases data from study of GDC-0084 into aggressive form of brain cancer

Director Interviews Full interview: Kazia Therapeutics releases data from study of GDC-0084 into aggressive form of brain cancer

on 24/11/19

Kazia Therapeutics Ltd - Kazia Therapeutics presents new data from Cantrixil Phase 1 Study in Ovarian Cancer at global conference

Director Interviews Full interview: Kazia Therapeutics presents new data from Cantrixil Phase 1 Study in Ovarian Cancer at global conference

on 30/9/19